Aristolochic Acid Herbs
When a Traditional Remedy Is Proven to Harm
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
This is the flagship case of rigorous science documenting that a traditional remedy causes serious harm. In the early 1990s, doctors in Belgium noticed a cluster of young women on a slimming regimen developing rapidly progressive kidney failure; the cause was traced to a slimming-clinic herb mix in which one plant was substituted for an Aristolochia species (the two shared a Pin Yin name). More than 100 Belgian patients were affected, roughly 70% progressed to end-stage kidney disease, and 40-46% developed urinary-tract cancer. The same disease was then documented on a large scale in Taiwan, tied to widespread herbal use, and corroborated by the specific DNA-adduct signature in tumor tissue. Aristolochic acid is now classified as a potent human carcinogen and Aristolochia herbs are banned or restricted in many countries.
Reference only. Not medical advice.
What can go wrong
This is a hard safety flag rather than a therapy. Aristolochic acid is a recognized human carcinogen and kidney toxin, and exposure can cause irreversible kidney failure and urinary-tract cancers that sometimes surface years after use has stopped. The danger is compounded by botanical substitution, since herbs that share common names can be swapped, so a product may contain an Aristolochia species without saying so. Anyone who has used Aristolochia-containing remedies, sometimes labeled with names such as Mu Tong, Fang Ji, Guang Fang Ji, or Asarum-based preparations, should tell a qualified clinician, who can advise on kidney monitoring and any needed urinary-tract screening. No traditional standing and no natural label offsets a recognized carcinogen.
If artemisinin shows that a herbal tradition can point toward a real cure, aristolochic acid shows the opposite with equal force. A plant with centuries of cultural standing turned out, under rigorous science, to cause irreversible kidney failure and cancer. In the early 1990s, physicians in Brussels traced a cluster of sudden kidney failure in young women to a slimming-clinic herbal mix in which an Aristolochia species had been swapped in by way of a shared common name. More than 100 people were affected, roughly 70 percent progressed to end-stage kidney disease, and among those studied surgically nearly half had urinary-tract cancer. The same toxin was later tied to a large problem in Taiwan, confirmed by a rare mutation fingerprint in patients' tumors, and shown to underlie the long-mysterious Balkan endemic nephropathy, where the plant contaminated wheat. Aristolochic acid is now a recognized human carcinogen, restricted or banned in many countries. Respect for a tradition does not override a proven, severe harm.
A respected herbal-medicine plant turned out to cause kidney failure and cancer, the clearest example of why cultural standing is not a safety guarantee.
How it works
Aristolochic acid forms DNA adducts that cause a distinctive pattern of mutations (including in the TP53 tumor-suppressor gene), driving both progressive kidney scarring and urothelial (urinary-tract) cancers. The DNA-adduct fingerprint is what let researchers prove causation.
What people get wrong
Often saidHerbal and natural remedies are inherently safe.
ActuallyAristolochic acid herbs are a definitive counterexample. A traditional, plant-derived preparation was shown to cause irreversible kidney failure and cancer, and IARC classifies it Group 1, carcinogenic to humans (Volume 82, 2002; Volume 100A, 2012). Natural and traditional are not safety claims.
Often saidIf a plant has been used for centuries, it must be harmless.
ActuallyAristolochia carried long classical standing, yet epidemiology in Belgium and Taiwan and molecular evidence in tumor tissue established it as a potent carcinogen. Long use can conceal slow, serious harm, so cultural age is not safety data.
Often saidA carcinogenic herb reveals itself quickly, so a product on the market must be fine.
ActuallyThe cancers and kidney failure can appear years after exposure has stopped (Nortier and colleagues, NEJM 2000). The Belgian and Balkan cases both show a long latency, which is one reason the harm went unrecognized for so long.
Often saidYou can tell whether a product contains it by reading the label.
ActuallyThe Belgian cluster arose because one herb was swapped for another under a shared common name, Fang Ji (Vanherweghem and colleagues, Lancet 1993). FDA testing in 2001 found aristolochic acid in botanical products that did not name it, which is why disclosure alone is not protection.
Who profits, and who pushes back
Vanherweghem et al. (The Lancet, 1993)
Identified rapidly progressive kidney fibrosis in young women on a slimming regimen containing Chinese herbs, the first link between Aristolochia and the disease.
Aristolochic-acid researchers
Tied the herb to large-scale kidney disease and urinary-tract cancer and proved causation through a specific DNA-adduct mutation signature in tumors.
Regulatory agencies
Classify aristolochic acid as a potent human carcinogen and ban or restrict Aristolochia-containing products, warning of botanical substitution risk.
Responsible TCM practitioners
Support removing Aristolochia species from the materia medica and improving botanical identification to prevent dangerous substitution.
Where the research comes from
Most of the published research on this comes from one place. 70% of it is from Belgian cohort developing kidney failure. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Belgian cohort developing kidney failure | 70% |
| Urothelial cancer in exposed | 45% |
How we got here
Aristolochia species had long-standing places in Chinese herbal practice and appear in Greek, Roman, and Ayurvedic writing, where the birthwort name reflects old use around childbirth. The modern harm story begins not in the clinic of antiquity but in the epidemiology of the 1990s. Belgian physicians reported in The Lancet in 1993 a cluster of rapidly progressive kidney fibrosis in young women who had followed the same Brussels slimming regimen, and traced it to an Aristolochia species substituted for the intended Stephania tetrandra under the shared name Fang Ji. Investigation then moved to Taiwan, where wide herbal use produced very high rates of kidney failure and upper urinary-tract cancer. Molecular work by Grollman and colleagues in 2007 detected the plant's DNA adducts in the kidneys of Balkan farming communities, solving a decades-old regional illness caused by seeds contaminating wheat. Many governments restricted or banned the herbs between 1999 and the mid-2000s.
- AntiquityAristolochia species recorded in Chinese, Greek, Roman, and Ayurvedic herbal practice
- 1993Vanherweghem and colleagues report in The Lancet a cluster of rapidly progressive kidney fibrosis in young women on a Brussels slimming regimen containing Chinese herbs
- 1994The intended Stephania tetrandra is identified as having been replaced by Aristolochia fangchi, sharing the common name Fang Ji
- 2000Nortier and colleagues report in the New England Journal of Medicine urothelial carcinoma in 18 of 39 Belgian nephropathy patients examined at surgery, a 46 percent prevalence
- 2001FDA issues an April consumer advisory urging people to stop using botanical products that contain aristolochic acid
- 2002IARC Monograph Volume 82 classifies herbal remedies containing Aristolochia as Group 1, carcinogenic to humans
- 2003Taiwan bans aristolochic-acid-containing herbal products after data show about a third of the population had been exposed
- 2007Grollman and colleagues detect aristolactam-DNA adducts in Balkan endemic nephropathy kidneys, tying the regional disease to dietary aristolochic acid
- 2012IARC Monograph Volume 100A reaffirms both aristolochic acid and plants containing it as Group 1; Chen and colleagues report the Taiwan urothelial-cancer signature in PNAS
- 2013Hoang and colleagues and Poon and colleagues independently define a rare A:T to T:A transversion mutational signature specific to aristolochic acid exposure
How it is understood
Plants in the Aristolochia family (and related Asarum) have long appeared in Chinese and other herbal traditions, used for conditions from edema to arthritis. They carry classical names and a place in the materia medica, which is exactly why the harm went unrecognized for so long: cultural standing is not a safety guarantee, and a respected traditional plant can still be deadly.
At a glance
- Toxin
- Aristolochic acid (DNA-adduct carcinogen)
- First cluster
- Belgian slimming clinic, early 1990s
- Progressed to kidney failure
- ~70% of that cohort
- Developed urinary-tract cancer
- ~40-46%
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Aristolochic Acid Herbs. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
Original 1993 Belgian cluster: rapidly progressive interstitial renal fibrosis in young women on a Chinese-herb slimming regimen
Urothelial carcinoma in 18 of 39 Belgian nephropathy patients at preventive surgery (46 percent); Stephania tetrandra replaced by Aristolochia fangchi
IARC classifies plants containing aristolochic acid and aristolochic acid itself as Group 1, carcinogenic to humans, with sufficient evidence in humans; TP53 A:T to T:A transversion signature
IARC Volume 82 (2002) Group 1 classification of herbal remedies containing Aristolochia
Aristolochic acid as the cause of Balkan endemic nephropathy; aristolactam-DNA adducts detected in patients' renal cortex
Taiwan: about a third of the population exposed 1997-2003; highest upper urinary-tract cancer incidence and the tumor mutational signature
Aristolochic-acid-associated urothelial cancer in Taiwan, PNAS 2012 (PMC listing)
Belgian cohort of more than 100 patients with about 70 percent reaching end-stage renal disease; substitution and Taiwan case detail
Whole-exome mutational signature of aristolochic acid exposure defined in urothelial tumors
Genome-wide mutational signature of aristolochic acid as a screening tool
FDA April 2001 consumer advisory to stop using aristolochic-acid-containing products; agency testing found contamination
Aristolochic Acid, an Herbal Carcinogen, Sold on the Web after FDA Alert, NEJM 2003
UK 1999 prohibition of Aristolochia in unlicensed herbal medicines and continued MHRA enforcement; EU bans 1999 onward
MHRA / GOV.UK Drug Safety Update on illegal herbal remedies containing Aristolochia
Reduction in urological cancer incidence in Taiwan after the 2003 ban on aristolochic-acid products
Reduction in the Incidence of Urological Cancers after the Ban, PMC
Aristolochic acid derivatives implicated in liver cancers across Asia, most intensely Taiwan (disputed liver-cancer link)
Overview and worldwide scope of aristolochic acid nephropathy, including Balkan prevalence figures
Aristolochic acid nephropathy: A worldwide problem, Kidney International